Searched for
JUBILANT PHARMOVA SHARES
Jubilant Pharmova shares decline 6% after Q1 profits falls 45% YoYJubilant Pharmova shares fell after Q1 profit plunged 45% YoY to Rs 56 crore, despite revenue rising 17% to Rs 2,229 crore. The profit decl...- Dividend alert! Last day to buy Bharti Airtel, Hero MotoCorp, among 43 stocks for dividend payout worth Rs 1,127As per Sebi's T+1 settlement cycle, investors must buy a company's shares at least one trading day before the record date to ensure the sha...
- Bonus, dividends and stock splits: Bharti Airtel, Hero MotoCorp among 88 stocks turning ex-date this week. Do you own any?Investors must hold shares in their demat accounts on the respective record dates to be eligible. Here is the complete day-wise list of key...
- Ahead of Market: 10 things that will decide stock market action on ThursdayIndian equities ended marginally higher after surrendering most intraday gains. Softer US inflation data supported sentiment, while elevate...
- Jubilant Group promoters to offload stakes in listed companies via block deals: ReportJubilant Group stake sale: The Bhartia family plans to offload stakes in Jubilant FoodWorks, Pharmova, and Ingrevia via block deals. The mo...
- Jubilant promoters eye Rs 2,000 crore via stake sales for Hindustan Coca-Cola Beverages dealJubilant Bhartia Group's promoters are selling minority stakes in listed companies to raise ₹2,000 crore for partially funding the acquisit...
- Stocks in news: HDFC Bank, Vodafone Idea, Dr Reddy's, RIL, IndiGoStocks in news: Domestic markets continued their rebound, gaining nearly half a percent on Tuesday, driven by a recovery in global indices....
- Stocks in news: Bajaj Finance, Kronox Lab, IDBI Bank, Dr Reddy's, Godawari Power, Jubilant PharmovaDomestic markets navigated a volatile week, ending near all-time highs. Bajaj Finance filed for a Rs 7,000 crore IPO, Kronox Lab to debut w...
- Jubilant Pharmova shares jump over 6% on receiving USFDA approval for Technetium Sulfur Colloid InjectionFor this approval, Jubilant is eligible for 180 days of exclusivity through the ‘Competitive Generic Therapy’ designation from the US FDA.
- Jubilant Pharmova shares tumble over 11% as Q4 net loss widens sequentially to Rs 98 croreJubilant Pharmova's quarterly net loss widened to INR 98 crore in the March quarter of FY23 from a loss of INR 15.67 crore in the previous ...
- Buy Jubilant Pharmova, target price Rs 475: Anand RathiJubilant Pharmova, incorporated in the year 1978, is a Mid Cap company (having a market cap of Rs 6501.86 Crore) operating in Pharmaceutica...
- Buy Jubilant Pharmova, target price Rs 417: ICICI SecuritiesJubilant Pharmova Ltd., incorporated in the year 1978, is a Mid Cap company (having a market cap of Rs 5304.06 Crore) operating in Pharmace...
- Market movers: The curious case of buying and selling in BSE sharesJubilant Pharmova announced that one of its subsidiaries received Abbreviated New Drug Application (ANDA) final approval for Doxepin Hydroc...
- Jubilant Pharmova Q2 net dips 3% to Rs 143 croreConsolidated total revenue from operations stood at Rs 1,657.45 crore in the second quarter as against Rs 1,591.35 crore in the year-ago pe...
- Jubilant Pharmova Q1 results: Co posts net profit of Rs 160 croreRevenue from continuing operations stood at Rs 1,634.65 crore in the quarter under review. It was Rs 1,156.07 crore in the same period a ye...
- Buy Jubilant Pharmova, target price Rs 920: Motilal OswalJubilant Pharmova Ltd., incorporated in the year 1978, is a Mid Cap company (having a market cap of Rs 11241.27 Crore) operating in Pharmac...
- USFDA issues import alert on Jubilant Pharmova's Roorkee plantThe US Food and Drug Administration (USFDA) has taken the action after conducting an inspection of the formulations plant in March this yea...
- Buy Jubilant Pharmova, target price Rs 960: Motilal OswalJubilant Pharmova Ltd., incorporated in the year 1978, is a Mid Cap company (having a market cap of Rs 11743.00 Crore) operating in Pharmac...
- Jubilant Pharmova posts Rs 214 cr profit in Q4Sales stood at Rs 1,552 crore for the fourth quarter while the same was at Rs 1,497 crore in the same period of FY20.
- Jubilant Pharmova surges as company develops Remdesivir oral formHospitals and pharmacists in major cities have reported acute shortage of the drug due to supply constraints and alleged hoarding.
Load More
